PC
KERX

PointState Capital’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

PointState Capital’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-500,000
Closed -$7.08M – 157
2014
Q4 		$7.08M Buy
+500,000
New +$7.75M 0.12% 88

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

PointState Capital's KERX Position: Q1 2015 in Review

PointState Capital sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2015, closing a stake of 500,000 shares — an estimated $7.08M sold.

PointState Capital first reported a position in KERX in Q4 2014 and held it in 1 quarter. The position peaked at $7.08M in Q4 2014. 157 funds tracked by Wall St. Rank hold KERX as of Q1 2015.

  • PointState Capital reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2015 after selling out during the quarter.
  • PointState Capital sold 500,000 Keryx Biopharmaceuticals Inc shares in Q1 2015, an estimated $7.08M.
  • PointState Capital first reported a position in Keryx Biopharmaceuticals Inc in Q4 2014 and held it in 1 quarter.
  • PointState Capital's Keryx Biopharmaceuticals Inc position peaked at $7.08M in Q4 2014.
  • 157 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2015.

Based on PointState Capital's 13F filing for Q1 2015, filed 15 May 2015.